Neuroscienze PharmaNess S.c.a r.l., Edificio 5, Loc. Piscinamanna, 09010, Pula, CA, Italy; Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK; KemoTech Srl, Edificio 3, Loc. Piscinamanna, 09010 Pula, CA, Italy.
Neuroscienze PharmaNess S.c.a r.l., Edificio 5, Loc. Piscinamanna, 09010, Pula, CA, Italy; Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK.
Eur J Med Chem. 2016 Oct 4;121:194-208. doi: 10.1016/j.ejmech.2016.05.011. Epub 2016 May 6.
8-Chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 9a was discovered as potent and selective CB1 antagonist by part of our group few years ago. In particular it was reported to have an affinity towards the CB1 cannabinoid receptor (CB1R), expressed as Ki, of 0.00035 nM. Nevertheless significantly divergent data were reported for the same compound from other laboratories. To unequivocally define the receptor profile of 9a, we have critically reviewed both its synthesis approach and binding data. Here we report that, in contrast to our previously reported data, 9a showed a Ki value for CB1R in the order of nanomolar rather than of fentomolar range. The new determined receptor profile of 9a was also ascertained for analogue derivatives 9b-i, as well as for 12. Moreover, the structural features of the synthesized compounds necessary for CB1R were investigated. Amongst the novel series, effects on CB1R intrinsic activity was highlighted due to the substituents at the position 3 of the pyrazole ring of the 1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole scaffold. Although the cannabinoid receptor profile of 9a was reviewed in this work, the relevance of this compound in CB1R antagonist based drug discovery is confirmed.
8-氯-1-(2',4'-二氯苯基)-N-哌啶-1-基-1,4,5,6-四氢苯并[6,7]环庚[1,2-c]吡唑-3-甲酰胺 9a 是我们小组几年前发现的一种有效的、选择性的 CB1 拮抗剂。特别是,据报道,它对 CB1 大麻素受体 (CB1R) 的亲和力(Ki)为 0.00035 nM。然而,来自其他实验室的相同化合物的数据却存在显著差异。为了明确 9a 的受体特征,我们对其合成方法和结合数据进行了严格的审查。在此,我们报告说,与我们之前报道的数据相反,9a 对 CB1R 的 Ki 值在纳摩尔范围内,而不是飞摩尔范围内。9a 的新确定的受体特征也在类似物衍生物 9b-i 以及 12 中得到了证实。此外,还研究了合成化合物对 CB1R 的结构特征。在所合成的化合物中,由于吡唑环 3 位的取代基,新型系列化合物对 CB1R 的内在活性产生了影响。尽管本工作对 9a 的大麻素受体特征进行了综述,但该化合物在基于 CB1R 拮抗剂的药物发现中的相关性得到了证实。